OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Research output: Contribution to journalArticleAcademicpeer-review

60 Citations (Scopus)
10 Downloads (Pure)

Abstract

Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p = 0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p = 0.045).
Original languageUndefined/Unknown
Pages (from-to)79-82
Number of pages4
JournalNeurogenetics
Volume12
Issue number1
DOIs
Publication statusPublished - 2011

Research programs

  • EMC MM-01-25-01
  • EMC MM-01-39-09-A
  • EMC NIHES-01-64-01
  • EMC NIHES-01-64-03
  • EMC NIHES-03-77-02
  • EMC OR-01-34-01

Cite this